UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

Blood, 2019-05, Vol.133 (19), p.2031-2042

2019

Link zum Volltext

Verfügbarkeit prüfen

Targeting Bruton’s Tyrosine Kinase in CLL

Frontiers in immunology, 2021-06, Vol.12, p.687458-687458

2021

Link zum Volltext

Verfügbarkeit prüfen

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

The New England journal of medicine, 2016-01, Vol.374 (4), p.323-332

2016

Link zum Volltext

Verfügbarkeit prüfen

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

Haematologica (Roma), 2017-10, Vol.102 (10), p.1796-1805

2017

Link zum Volltext

Verfügbarkeit prüfen

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

Nature communications, 2016-05, Vol.7 (1), p.11589-11589, Article 11589

2016

Link zum Volltext

Verfügbarkeit prüfen

Ventricular arrhythmias and sudden death in patients taking ibrutinib

Blood, 2017-05, Vol.129 (18), p.2581-2584

2017

Link zum Volltext

Verfügbarkeit prüfen

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

Blood, 2016-06, Vol.127 (25), p.3215-3224

2016

Link zum Volltext

Verfügbarkeit prüfen

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

Journal of clinical oncology, 2012-02, Vol.30 (5), p.488-496

2012

Link zum Volltext

Verfügbarkeit prüfen

Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells

Nature (London), 2017-02, Vol.542 (7642), p.489-493

2017

Link zum Volltext

Verfügbarkeit prüfen

Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia

Cancer cell, 2018-12, Vol.34 (6), p.982-995.e7

2018

Link zum Volltext

Verfügbarkeit prüfen

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

Molecular cancer, 2023-08, Vol.22 (1), p.1-138, Article 138

2023

Link zum Volltext

Verfügbarkeit prüfen

Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation

Clinical cancer research, 2017-02, Vol.23 (3), p.735-745

2017

Link zum Volltext

Verfügbarkeit prüfen

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib

Blood, 2016-06, Vol.127 (25), p.3237-3252

2016

Link zum Volltext

Verfügbarkeit prüfen

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737

The Journal of clinical investigation, 2007-01, Vol.117 (1), p.112-121

2007

Link zum Volltext

Verfügbarkeit prüfen

How I treat CLL patients with ibrutinib

Blood, 2018-01, Vol.131 (4), p.379-386

Brown, Jennifer R.

2018

Link zum Volltext

Verfügbarkeit prüfen

Clonal architecture of CXCR4 WHIM‐like mutations in Waldenström Macroglobulinaemia

British journal of haematology, 2016-03, Vol.172 (5), p.735-744

2016

Link zum Volltext

Verfügbarkeit prüfen

Nanowire-Mediated Delivery Enables Functional Interrogation of Primary Immune Cells: Application to the Analysis of Chronic Lymphocytic Leukemia

Nano letters, 2012-12, Vol.12 (12), p.6498-6504

2012

Link zum Volltext

Verfügbarkeit prüfen

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice

Frontiers in oncology, 2021-11, Vol.11, p.720704-720704

2021

Link zum Volltext

Verfügbarkeit prüfen

LNA-mediated anti–miR-155 silencing in low-grade B-cell lymphomas

Blood, 2012-08, Vol.120 (8), p.1678-1686

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 3.096

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.887)
Mit Volltextzugriff
(2.714)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(285)
Journal Of Clinical Oncology
(75)
Plos One
(48)
The New England Journal Of Medicine
(46)
Diabetes Care
(37)
Nature Communications
(30)
Cancer Research
(28)
Clinical Lymphoma, Myeloma And Leukemia
(28)
Leukemia & Lymphoma
(26)
Science
(26)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

Targeting Bruton’s Tyrosine Kinase in CLL

Locally Disordered Methylation Forms the Basis of Intratumor Methylome Variation in Chronic Lymphocytic Leukemia

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

Ventricular arrhythmias and sudden death in patients taking ibrutinib

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells

MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737

How I treat CLL patients with ibrutinib

Clonal architecture of CXCR4 WHIM‐like mutations in Waldenström Macroglobulinaemia

Nanowire-Mediated Delivery Enables Functional Interrogation of Primary Immune Cells: Application to the Analysis of Chronic Lymphocytic Leukemia

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice

LNA-mediated anti–miR-155 silencing in low-grade B-cell lymphomas

Suchergebnisse filtern